Revenue of Lundbeck top products 2021-2023

Among products of Danish pharmaceutical company Lundbeck, the second highest revenue in 2023 was generated by Brintellix/Trintellix. The revenues from Brintellix/Trintellix reached roughly 4.3 billion Danish kroner that year. It was topped by Rexulti/Rxulti, with a revenue of 4.5 billion Danish kroner. H. Lundbeck A/S is a Danish pharmaceutical company founded in 1915 with its headquarter in Copenhagen. The key products produced by the company are pharmaceuticals for the nervous system.

在丹麦制药公司Lundbeck的产品系列中，Brintellix/Trintellix在2023年创造了第二高的收入。当年，Brintellix/Trintellix的营收约为43亿丹麦克朗。其收入被Rexulti/Rxulti超越，后者营收达到了45亿丹麦克朗。H. Lundbeck A/S是一家成立于1915年的丹麦制药公司，总部位于哥本哈根。公司主要生产针对神经系统的药物。